Plasma olfactomedin 4 level in peripheral blood and its association with clinical features of breast cancer

Liu,Chaoqian; Guo,Yan; Wu,Weiwei; Zhang,Zhenzhen; Xu,Lu; Wu,Kainan; Hu,Wei; Liu,Guoping; Shi,Junyi; Xu,Cheng; Bi,Jianwei; Sheng,Yuan

doi:10.3892/ol.2017.7193

Plasma olfactomedin 4 level in peripheral blood and its association with clinical features of breast cancer

Authors:
- Chaoqian Liu
- Yan Guo
- Weiwei Wu
- Zhenzhen Zhang
- Lu Xu
- Kainan Wu
- Wei Hu
- Guoping Liu
- Junyi Shi
- Cheng Xu
- Jianwei Bi
- Yuan Sheng
View Affiliations

Affiliations: Department of Breast Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China, Department of Endocrinology, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China, Biotecan Medical Diagnostics Co., Ltd, Zhangjiang Center for Translational Medicine, Shanghai 200120, P.R. China, Department of General Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China
Published online on: October 16, 2017 https://doi.org/10.3892/ol.2017.7193
Pages: 8106-8113

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression of olfactomedin 4 (OLFM4) in plasma of patients with breast cancer and its association with diagnosis, metastasis and prognosis of breast cancer. OLFM4 gene expression level of peripheral blood plasma in 60 patients with breast cancer and 26 healthy donors was examined by ELISA. The expression of OLFM4 in tumor tissues of patients with breast cancer was evaluated by immunohistochemistry (protein expression) and reverse transcription‑quantitative polymerase chain reaction (mRNA expression), respectively. Circulating tumor cells (CTCs) were detected in a certain set of patients. The expression of OLFM4 in plasma of the overall healthy people was higher compared with patients with breast cancer. The plasma OLFM4 level in patients with breast cancer was consistent with the expression of OLFM4 protein in tumor tissues (R2=1), indicating that the level of plasma OLFM4 expression may represent the expression of OLFM4 in breast cancer tissues. The plasma OLFM4 level in patients with histological grade I was significantly lower compared with grade III (P<0.05). Breast cancer patients with positive CTC were associated with low level of plasma OLFM4. These results suggest that low OLFM4 expression in plasma or tissue specimens of breast cancer patients is more likely to represent low histological differentiation and decreased invasive/metastatic capabilities. Taken together, plasma OLFM4 level may be considered as a biomarker for diagnosis and prognosis of breast cancer for cases where there are difficulties in obtaining tumor tissue samples.

View Figures

View References

1	Grover PK, Hardingham JE and Cummins AG: Stem cell marker olfactomedin 4: Critical appraisal of its characteristics and role in tumorigenesis. Cancer Metastasis Rev. 29:761–775. 2010. View Article : Google Scholar : PubMed/NCBI
2	Kulkarni NH, Karavanich CA, Atchley WR and Anholt RR: Characterization and differential expression of a human gene family of olfactomedin-related proteins. Genet Res. 76:41–50. 2000. View Article : Google Scholar : PubMed/NCBI
3	Zhang J, Liu WL, Tang DC, Chen L, Wang M, Pack SD, Zhuang Z and Rodgers GP: Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene. 283:83–93. 2002. View Article : Google Scholar : PubMed/NCBI
4	Tomarev SI and Nakaya N: Olfactomedin domain-containing proteins: Possible mechanisms of action and functions in normal development and pathology. Mol Neurobiol. 40:122–138. 2009. View Article : Google Scholar : PubMed/NCBI
5	Besson D, Pavageau AH, Valo I, Bourreau A, Bélanger A, Eymerit-Morin C, Moulière A, Chassevent A, Boisdron-Celle M, Morel A, et al: A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker. Mol Cell Proteomics. 10:M111.0097122011. View Article : Google Scholar : PubMed/NCBI
6	Huang Y, Yang M, Yang H and Zeng Z: Upregulation of the GRIM-19 gene suppresses invasion and metastasis of human gastric cancer SGC-7901 cell line. Exp Cell Res. 316:2061–2070. 2010. View Article : Google Scholar : PubMed/NCBI
7	Kobayashi D, Koshida S, Moriai R, Tsuji N and Watanabe N: Olfactomedin 4 promotes S-phase transition in proliferation of pancreatic cancer cells. Cancer Sci. 98:334–340. 2007. View Article : Google Scholar : PubMed/NCBI
8	Liu W, Liu Y, Zhu J, Wright E, Ding I and Rodgers GP: Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma. Clin Cancer Res. 14:1041–1049. 2008. View Article : Google Scholar : PubMed/NCBI
9	Park KS, Kim KK, Piao ZH, Kim MK, Lee HJ, Kim YC, Lee KS, Lee JH and Kim KE: Olfactomedin 4 suppresses tumor growth and metastasis of mouse melanoma cells through downregulation of integrin and MMP genes. Mol Cells. 34:555–561. 2012. View Article : Google Scholar : PubMed/NCBI
10	Koshida S, Kobayashi D, Moriai R, Tsuji N and Watanabe N: Specific overexpression of OLFM4 (GW112/HGC-1) mRNA in colon, breast and lung cancer tissues detected using quantitative analysis. Cancer Sci. 98:315–320. 2007. View Article : Google Scholar : PubMed/NCBI
11	Oue N, Sentani K, Noguchi T, Ohara S, Sakamoto N, Hayashi T, Anami K, Motoshita J, Ito M, Tanaka S, et al: Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer. 125:2383–2392. 2009. View Article : Google Scholar : PubMed/NCBI
12	Yu L, He M, Yang Z, Chen G, Li M, Wang L and Chen S: Olfactomedin 4 is a marker for progression of cervical neoplasia. Int J Gynecol Cancer. 21:367–372. 2011. View Article : Google Scholar : PubMed/NCBI
13	Chen L, Li H, Liu W, Zhu J, Zhao X, Wright E, Cao L, Ding I and Rodgers GP: Olfactomedin 4 suppresses prostate cancer cell growth and metastasis via negative interaction with cathepsin D and SDF-1. Carcinogenesis. 32:986–994. 2011. View Article : Google Scholar : PubMed/NCBI
14	Yan H, Lu D, Xu L, Xie Q, Dong X and Wu Y: Increased expression level of Olfactomedin4 in peripheral blood mononuclear cells of pancreatic adenocarcinoma patients. Hepatogastroenterology. 58:1354–1359. 2011. View Article : Google Scholar : PubMed/NCBI
15	Huang MY, Wang HM, Chang HJ, Hsiao CP, Wang JY and Lin SR: Overexpression of S100B, TM4SF4, and OLFM4 genes is correlated with liver metastasis in Taiwanese colorectal cancer patients. DNA Cell Biol. 31:43–49. 2012. View Article : Google Scholar : PubMed/NCBI
16	Huang MY, Wang HM, Tok TS, Chang HJ, Chang MS, Cheng TL, Wang JY and Lin SR: EVI2B, ATP2A2, S100B, TM4SF3, and OLFM4 as potential prognostic markers for postoperative Taiwanese colorectal cancer patients. DNA Cell Biol. 31:625–635. 2012. View Article : Google Scholar : PubMed/NCBI
17	Xiong B, Lei X, Zhang L and Fu J: The clinical significance and biological function of olfactomedin 4 in triple negative breast cancer. Biomed Pharmacother. 86:67–73. 2017. View Article : Google Scholar : PubMed/NCBI
18	Amin MB, Edge SB, Greene FL, Schilsky RL, Gaspar LE, Washington MK, Sullivan DC, Brookland RK, Brierley JD, Balch CM, et al: AJCC (American Joint Committee on Cancer) Cancer Staging Manual. 8th edition. Springer; Chicago: 2017, View Article : Google Scholar
19	Li Y, Zhang X, Ge S, Gao J, Gong J, Lu M, Zhang Q, Cao Y, Wang DD, Lin PP and Shen L: Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. Oncotarget. 5:6594–6602. 2014. View Article : Google Scholar : PubMed/NCBI
20	Zhang Y, Wang F, Ning N, Chen Q, Yang Z, Guo Y, Xu D, Zhang D, Zhan T and Cui W: Patterns of circulating tumor cells identified by CEP8, CK and CD45 in pancreatic cancer. Int J Cancer. 136:1228–1233. 2015. View Article : Google Scholar : PubMed/NCBI
21	Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW and Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Abayomi K, Gelman A and Levy M: Diagnostics for multivariate imputations. Series C Appl Stat. 57:273–291. 2008. View Article : Google Scholar
24	Conover WJ: Practical nonparametric statistics. 2nd edition. New York: Wiley; 1980
25	Yu L, Wang L and Chen S: Olfactomedin 4, a novel marker for the differentiation and progression of gastrointestinal cancers. Neoplasma. 58:9–13. 2011. View Article : Google Scholar : PubMed/NCBI
26	Snyder DA, Rivers AM, Yokoe H, Menco BP and Anholt RR: Olfactomedin: Purification, characterization, and localization of a novel olfactory glycoprotein. Biochemistry. 30:9143–9153. 1991. View Article : Google Scholar : PubMed/NCBI
27	Liu W, Yan M, Liu Y, Wang R, Li C, Deng C, Singh A, Coleman WG Jr and Rodgers GP: Olfactomedin 4 down-regulates innate immunity against Helicobacter pylori infection. Proc Natl Acad Sci USA. 107:pp. 11056–11061. 2010, View Article : Google Scholar : PubMed/NCBI
28	Révillion F, Pawlowski V, Hornez L and Peyrat JP: Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer. Eur J Cancer. 36:1038–1042. 2000. View Article : Google Scholar : PubMed/NCBI
29	Radonić A, Thulke S, Mackay IM, Landt O, Siegert W and Nitsche A: Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun. 313:856–862. 2004. View Article : Google Scholar : PubMed/NCBI
30	Takadate T, Onogawa T, Fukuda T, Motoi F, Suzuki T, Fujii K, Kihara M, Mikami S, Bando Y, Maeda S, et al: Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues. Int J Cancer. 132:1368–1382. 2013. View Article : Google Scholar : PubMed/NCBI
31	Liu RH, Yang MH, Xiang H, Bao LM, Yang HA, Yue LW, Jiang X, Ang N, Wu LY and Huang Y: Depletion of OLFM4 gene inhibits cell growth and increases sensitization to hydrogen peroxide and tumor necrosis factor-alpha induced-apoptosis in gastric cancer cells. J Biomed Sci. 19:382012. View Article : Google Scholar : PubMed/NCBI
32	Suh YS, Lee HJ, Jung EJ, Kim MA, Nam KT, Goldenring JR, Yang HK and Kim WH: The combined expression of metaplasia biomarkers predicts the prognosis of gastric cancer. Ann Surg Oncol. 19:1240–1249. 2012. View Article : Google Scholar : PubMed/NCBI
33	de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW and Span PN: Normalization of gene expression measurements in tumor tissues: Comparison of 13 endogenous control genes. Lab Invest. 85:154–159. 2005. View Article : Google Scholar : PubMed/NCBI
34	Lyng MB, Laenkholm AV, Pallisgaard N and Ditzel HJ: Identification of genes for normalization of real-time RT-PCR data in breast carcinomas. BMC Cancer. 8:202008. View Article : Google Scholar : PubMed/NCBI
35	Gresner P, Gromadzinska J and Wasowicz W: Reference genes for gene expression studies on non-small cell lung cancer. Acta Biochim Pol. 56:307–316. 2009.PubMed/NCBI
36	Caradec J, Sirab N, Keumeugni C, Moutereau S, Chimingqi M, Matar C, Revaud D, Bah M, Manivet P, Conti M and Loric S: ‘Desperate house genes’: The dramatic example of hypoxia. Br J Cancer. 102:1037–1043. 2010. View Article : Google Scholar : PubMed/NCBI
37	Liu W, Chen L, Zhu J and Rodgers GP: The glycoprotein hGC-1 binds to cadherin and lectins. Exp Cell Res. 312:1785–1797. 2006. View Article : Google Scholar : PubMed/NCBI